Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations

Guy Webster, Phoebe Rich, Michael H. Gold, Serena Mraz, Barry Calvarese, Diana Chen

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Oral antibiotics are commonly prescribed for moderate or severe acne, but there may be limitations due to concerns about side effects associated with systemic treatments. Objective: To evaluate the efficacy and safety of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BP 2.5%) aqueous gel in the treatment of moderate or severe acne subpopulations. Methods: Two multicenter, double-blind studies randomized 2,813 subjects with moderate or severe acne to clindamycin-BP 2.5% gel, each active ingredient, or vehicle gel, once daily for 12 weeks. Efficacy evaluations included inflammatory and non-inflammatory lesion counts and evaluator's global severity score at baseline and weeks 4, 8 and 12. Adverse events and subjects' evaluations of product tolerability were also monitored. Subpopulation efficacy and safety analyses by baseline acne severity were performed for the combined data from the two phase 3 studies. Results: Clindamycin-BP 2.5% gel significantly reduced inflammatory, non-inflammatory and total lesions compared with each active ingredient and vehicle in subjects with moderate acne and compared with vehicle in severe acne subjects at week 12. Significant improvements in evaluator's global severity score were evident for subjects with moderate acne in the clindamycin-BP 2.5% group compared with each active ingredient and vehicle and compared with vehicle in subjects with severe acne at week 12. Rates of adverse events were low and similar between treatment groups and baseline acne severity. Conclusion: Clindamycin-BP 2.5% aqueous gel is an effective and safe once-daily treatment for moderate or severe acne.

Original languageEnglish (US)
Pages (from-to)736-743
Number of pages8
JournalJournal of Drugs in Dermatology
Volume8
Issue number8
StatePublished - Aug 1 2009
Externally publishedYes

Fingerprint

Benzoyl Peroxide
Acne Vulgaris
Gels
Clindamycin
clindamycin phosphate
Safety
Double-Blind Method

ASJC Scopus subject areas

  • Dermatology

Cite this

Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. / Webster, Guy; Rich, Phoebe; Gold, Michael H.; Mraz, Serena; Calvarese, Barry; Chen, Diana.

In: Journal of Drugs in Dermatology, Vol. 8, No. 8, 01.08.2009, p. 736-743.

Research output: Contribution to journalArticle

@article{36e5f8c97232469f885b502dcaea1fce,
title = "Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2{\%}) and low concentration benzoyl peroxide (2.5{\%}) aqueous gel in moderate or severe acne subpopulations",
abstract = "Background: Oral antibiotics are commonly prescribed for moderate or severe acne, but there may be limitations due to concerns about side effects associated with systemic treatments. Objective: To evaluate the efficacy and safety of a fixed combination clindamycin phosphate 1.2{\%} and benzoyl peroxide 2.5{\%} (clindamycin-BP 2.5{\%}) aqueous gel in the treatment of moderate or severe acne subpopulations. Methods: Two multicenter, double-blind studies randomized 2,813 subjects with moderate or severe acne to clindamycin-BP 2.5{\%} gel, each active ingredient, or vehicle gel, once daily for 12 weeks. Efficacy evaluations included inflammatory and non-inflammatory lesion counts and evaluator's global severity score at baseline and weeks 4, 8 and 12. Adverse events and subjects' evaluations of product tolerability were also monitored. Subpopulation efficacy and safety analyses by baseline acne severity were performed for the combined data from the two phase 3 studies. Results: Clindamycin-BP 2.5{\%} gel significantly reduced inflammatory, non-inflammatory and total lesions compared with each active ingredient and vehicle in subjects with moderate acne and compared with vehicle in severe acne subjects at week 12. Significant improvements in evaluator's global severity score were evident for subjects with moderate acne in the clindamycin-BP 2.5{\%} group compared with each active ingredient and vehicle and compared with vehicle in subjects with severe acne at week 12. Rates of adverse events were low and similar between treatment groups and baseline acne severity. Conclusion: Clindamycin-BP 2.5{\%} aqueous gel is an effective and safe once-daily treatment for moderate or severe acne.",
author = "Guy Webster and Phoebe Rich and Gold, {Michael H.} and Serena Mraz and Barry Calvarese and Diana Chen",
year = "2009",
month = "8",
day = "1",
language = "English (US)",
volume = "8",
pages = "736--743",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "8",

}

TY - JOUR

T1 - Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations

AU - Webster, Guy

AU - Rich, Phoebe

AU - Gold, Michael H.

AU - Mraz, Serena

AU - Calvarese, Barry

AU - Chen, Diana

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Background: Oral antibiotics are commonly prescribed for moderate or severe acne, but there may be limitations due to concerns about side effects associated with systemic treatments. Objective: To evaluate the efficacy and safety of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BP 2.5%) aqueous gel in the treatment of moderate or severe acne subpopulations. Methods: Two multicenter, double-blind studies randomized 2,813 subjects with moderate or severe acne to clindamycin-BP 2.5% gel, each active ingredient, or vehicle gel, once daily for 12 weeks. Efficacy evaluations included inflammatory and non-inflammatory lesion counts and evaluator's global severity score at baseline and weeks 4, 8 and 12. Adverse events and subjects' evaluations of product tolerability were also monitored. Subpopulation efficacy and safety analyses by baseline acne severity were performed for the combined data from the two phase 3 studies. Results: Clindamycin-BP 2.5% gel significantly reduced inflammatory, non-inflammatory and total lesions compared with each active ingredient and vehicle in subjects with moderate acne and compared with vehicle in severe acne subjects at week 12. Significant improvements in evaluator's global severity score were evident for subjects with moderate acne in the clindamycin-BP 2.5% group compared with each active ingredient and vehicle and compared with vehicle in subjects with severe acne at week 12. Rates of adverse events were low and similar between treatment groups and baseline acne severity. Conclusion: Clindamycin-BP 2.5% aqueous gel is an effective and safe once-daily treatment for moderate or severe acne.

AB - Background: Oral antibiotics are commonly prescribed for moderate or severe acne, but there may be limitations due to concerns about side effects associated with systemic treatments. Objective: To evaluate the efficacy and safety of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BP 2.5%) aqueous gel in the treatment of moderate or severe acne subpopulations. Methods: Two multicenter, double-blind studies randomized 2,813 subjects with moderate or severe acne to clindamycin-BP 2.5% gel, each active ingredient, or vehicle gel, once daily for 12 weeks. Efficacy evaluations included inflammatory and non-inflammatory lesion counts and evaluator's global severity score at baseline and weeks 4, 8 and 12. Adverse events and subjects' evaluations of product tolerability were also monitored. Subpopulation efficacy and safety analyses by baseline acne severity were performed for the combined data from the two phase 3 studies. Results: Clindamycin-BP 2.5% gel significantly reduced inflammatory, non-inflammatory and total lesions compared with each active ingredient and vehicle in subjects with moderate acne and compared with vehicle in severe acne subjects at week 12. Significant improvements in evaluator's global severity score were evident for subjects with moderate acne in the clindamycin-BP 2.5% group compared with each active ingredient and vehicle and compared with vehicle in subjects with severe acne at week 12. Rates of adverse events were low and similar between treatment groups and baseline acne severity. Conclusion: Clindamycin-BP 2.5% aqueous gel is an effective and safe once-daily treatment for moderate or severe acne.

UR - http://www.scopus.com/inward/record.url?scp=70349250145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349250145&partnerID=8YFLogxK

M3 - Article

C2 - 19663111

AN - SCOPUS:70349250145

VL - 8

SP - 736

EP - 743

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 8

ER -